medcelerator · clinician one-pager

Pill for Teens and Adults with Severe Alopecia Areata

Olumiant (baricitinib) — once-daily pill for teens and adults with severe alopecia areata

FDA Approved · United States, European Union · October 11, 2026

Condition: Alopecia Areata

Who this is for

This is for families and adults living with severe alopecia areata who are 12 years or older. It explains the US prescribing-information expansion in September 2026 that added adolescents to Olumiant (baricitinib), the EU SmPC adolescent wording, the once-daily oral path through dermatology, and what BRAVE-AA-PEDS showed. It is not an under-12 approval, not a cream, and not a reason to skip infection and lab screening. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In the European Union, authorisation is not confirmed; see Possible routes below if any are listed.

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/olumiant-baricitinib-adolescent-aa